Whitehawk Therapeutics, Inc. 8-K

What Happened

• On March 12, 2026, Whitehawk Therapeutics, Inc. (WHWK) issued a press release announcing its financial results for the fiscal year ended December 31, 2025. The press release was furnished as Exhibit 99.1 to the company’s Form 8‑K under Item 2.02 (Results of Operations and Financial Condition).
• The Form 8‑K also includes the Item 9.01 statement clarifying that the furnished press release (Exhibit 99.1) is “furnished” and not “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except by specific reference.

Key Details

• Filing date: March 12, 2026 (Form 8‑K, Accession No. 0001193125-26-103117).
• Reporting period: Fiscal year ended December 31, 2025.
• Press release attached as Exhibit 99.1 and incorporated by reference into the 8‑K.
• Legal note under Item 9.01: furnished information is not subject to Section 18 liability and is not automatically incorporated into other SEC filings.

Why It Matters

• This 8‑K furnishes Whitehawk’s latest published earnings and financial condition for FY2025; investors should read Exhibit 99.1 for detailed figures on revenue, net income (or loss), cash position and any management commentary or outlook.
• Because the document is furnished (not “filed”), it carries the company’s disclosure but has limited Section 18 liability; nevertheless, the information can materially affect investor decisions and may influence share price and analyst expectations.
• Action for investors: review the attached press release (Exhibit 99.1) and monitor subsequent SEC filings (e.g., Form 10‑K) for audited financial statements and additional detail.